Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294941 · ClinicalTrials.gov registry record · Phase 2
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
A Phase 2 study, sponsored by HepQuant.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT03294941 is a Phase 2 study that was terminated before completion, run by HepQuant. The registered enrollment target is 17 participants.
The verdict
NCT03294941, a Phase 2 study, was terminated before completion, sponsored by HepQuant.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination product. Enrollment into one of the 3 Gilead Selonsertib clinical trials (GS-US-416-2124, GS-US-384-1943/1944) is required for enrollment into the HepQuant study
Interventions
- COMBINATION_PRODUCT HepQuant SHUNT Liver Diagnostic Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-12-08 |
| Est. Completion | 2019-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294941
The ClinicalTrials.gov registry entry for NCT03294941 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HepQuant, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HepQuant SHUNT Liver Diagnostic Kit is the first listed.
NCT03294941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03294941 about?
NCT03294941 is a clinical study titled "The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology". The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination product. Enrollment into one of the 3 Gilead Selonsertib clinical tri...
What is the current status of trial NCT03294941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2017-12-08. Estimated completion is 2019-09-11.
What interventions are being tested in trial NCT03294941?
The interventions under investigation include: HepQuant SHUNT Liver Diagnostic Kit (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03294941?
This trial is sponsored by HepQuant, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.